About Us
10th of November, 2017, the Annual Summary meeting of National Key research project --- “Common single gene diseases and gene group diseases non-invasive prenatal detection and diagnostics technology platforms development and standardization project”, was conducted in Beijing PLA hospital. Beijing San Valley technologies Ltd., reported its findings and progress from last year to all attending experts as a participant in the project.
As data from “China Birth-defect prevention and treatment Report” indicates, the rate of occurrence of birth-defect are about 5.6%, with a yearly occurrence of 900,000 new cases. Birth-defect severely impact the survival probability and life quality of infants; by its nature, birth-defects are difficult to treat, and the emphasis should be placed on prevention methods. As a National Key Research Project, the “Common single gene diseases and gene group diseases non-invasive prenatal detection and diagnostics technology platforms development and standardization project” aims to provide solution to counter the fact that our country faces high rate birth-defect, lacking a complete set of non-invasive prenatal testing technologies; and, to discuss and further the methodology of preemptive prevention and treatment of single gene and gene group diseases.
At the beginning of the meeting, leaders from the National Health and Family Planning Commission expressed its expectation and suggestions for the project. Dr. Dai Pu from Beijing PLA hospital reported the overall progress of the project as the principal leading official. Afterwards, each leading officials of each subsidiary subject reported the progress of their respective subjects.
Within this key project, San Valley participates in the subject of systematically standardizing non-invasive prenatal testing and diagnostics in clinical applications. Our chief responsibility is to develop test kits and software for detection of contamination in laboratory testing platforms, under a unified testing platform for common single-gene and gene group diseases
During the meeting, Technical officer of San Valley Mr. Wang Xueliang reported the project’s progress and overall situation in detail. Other participants of the project also give report on their respective sections of the project regarding their progress, future plans, personnel, funding support and other managerial situations. After one-year of effort, San Valley has completed its assigned subject in accordance to the given quality perimeter, creating a contamination related gene-fingerprint database, a contamination quality control testing kit, independently created software for detection and analysis of the nature, quantity and source of contamination, its sensitivity reaches 0.1%, and compatible with multiple different PCR platforms.
At the end of the meeting, the leading personnel of each sub-projects initiated discussions between the representatives of each project, they expressed and exchanged their questions, confusions, and what’s the next step for their respective projects.
The successful ending of the summary meet paved the solid foundation for the next step within the project. Expert opinions and suggestions have also raised the standards of work for the future. We believe this meeting has contributed in the ensuring the success of the National “Thirteen’s Five year” birth-defect prevention and treatment project.